WuXi Biologics

Jacobs has been selected to provide construction management services for WuXi Biologics' new biologics drug substance manufacturing facility in Dundalk, Ireland. The facility is estimated to cost more than $394 million and will create 400 highly skilled jobs.

WuXi Biologics and Amicus Therapeutics have entered into an exclusive commercial manufacturing partnership for Amicus' Pompe biologic ATB200. WuXi Biologics will be the exclusive commercial drug substance manufacturing partner and key commercial drug product supplier.

WuXi Biologics commenced construction of a new biologics drug substance manufacturing facility in Dundalk, Ireland. The facility will have a total capacity of 48,000L fed-batch and 6,000L perfusion using single-use bioreactors.

WuXi Biologics will invest $60 million and hire 150 employees to build a biologics manufacturing facility in Worcester, Massachusetts, its first U.S. site, announced June 10, 2018.

WuXi Biologics announced plans to build a biologics development, clinical and commercial manufacturing center in Shijiazhuang, Hebei province, with 5,000 L and 48,000 L bioreactor capacity. The initial phase will be operational in 2020.

WuXi Biologics will invest €325 million to build a new biologics drug substance manufacturing facility in Dundalk, Ireland, creating 400 jobs over five years. The facility will use single-use bioreactors and is the company's first site outside China.